Filing Flows › Viatris (VTRS) › EpiPen® Auto-Injectors revenue
Viatris (VTRS) EpiPen® Auto-Injectors revenue by quarter
Viatris' EpiPen® Auto-Injectors revenue was $156M in Q3 2026 (third quarter 2026), +54% from Q1 2026. Over the last 4 quarters it ranged from $101M (Q1 2026) to $157M (Q3 2025).
| Quarter | EpiPen® Auto-Injectors revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $156M | +54% | -0.9% |
| Q1 2026 | $101M | -36% | — |
| Q3 2025 | $157M | +15% | — |
| Q2 2025 | $137M | — | — |
Q3 2026 at a glance
Viatris, Q3 2026: revenue $3.7B (-0.3% year over year), operating margin 7.0%, net loss $325M, operating cash flow $899M. The chart follows the revenue to costs, profit and cash.
Questions
What is Viatris' EpiPen® Auto-Injectors revenue?
Viatris' EpiPen® Auto-Injectors revenue was $156M in Q3 2026 (third quarter 2026), +54% from Q1 2026.
How has Viatris' EpiPen® Auto-Injectors revenue changed?
Over the last 4 quarters it ranged from $101M (Q1 2026) to $157M (Q3 2025).